AbbVie (ABBV) Cash from Investing Activities (2012 - 2026)
AbbVie (ABBV) reported Cash from Investing Activities of -$574.0 million for Q1 2026, up 21.9% year-over-year from -$470.9 million in Q1 2025, and up 60.77% on a QoQ basis from -$1.5 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Cash from Investing Activities data on file, last reported at -$574.0 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 21.9% year-over-year to -$574.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 billion (up 45.83% YoY) and the FY2025 annual result came in at -$6.6 billion, up 68.09% from the prior year.
- Cash from Investing Activities improved to -$574.0 million in Q1 2026 per ABBV's latest filing, from -$1.5 billion in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.3 billion in Q3 2022 and bottomed at -$9.6 billion in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$800.0 million (2023), against an average of -$1.8 billion.
- The widest annual swing landed in 2022, when Cash from Investing Activities soared 309.11%; it then plunged 2137.4% in 2024.
- Tracing ABBV's Cash from Investing Activities over 5 years: stood at -$448.0 million in 2022, then sank by 78.57% to -$800.0 million in 2023, then tumbled by 134.25% to -$1.9 billion in 2024, then climbed by 21.93% to -$1.5 billion in 2025, then jumped by 60.77% to -$574.0 million in 2026.
- Per Business Quant, the three latest ABBV Cash from Investing Activities figures stand at -$574.0 million (Q1 2026), -$1.5 billion (Q4 2025), and -$3.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -3.92 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | -1.04 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -574.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -131.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -574.00 Mn |
| Mar 31, 2026 | -574.00 Mn |
| Dec 31, 2025 | -1.46 Bn |
| Dec 31, 2025 | -1.46 Bn |
| Sep 30, 2025 | -3.26 Bn |
| Sep 30, 2025 | -3.26 Bn |
| Jun 30, 2025 | -1.18 Bn |
| Jun 30, 2025 | -1.18 Bn |
| Mar 31, 2025 | -735.00 Mn |
| Mar 31, 2025 | -735.00 Mn |
| Dec 31, 2024 | -1.87 Bn |
| Dec 31, 2024 | -1.87 Bn |
| Sep 30, 2024 | -8.26 Bn |
| Sep 30, 2024 | -8.26 Bn |
| Jun 30, 2024 | -1.10 Bn |
| Jun 30, 2024 | -1.10 Bn |
| Mar 31, 2024 | -9.59 Bn |
| Mar 31, 2024 | -9.59 Bn |
| Dec 31, 2023 | -800.00 Mn |
| Dec 31, 2023 | -800.00 Mn |
| Sep 30, 2023 | -369.00 Mn |
| Sep 30, 2023 | -369.00 Mn |
| Jun 30, 2023 | -341.00 Mn |
| Jun 30, 2023 | -341.00 Mn |
| Mar 31, 2023 | -499.00 Mn |
| Mar 31, 2023 | -499.00 Mn |
| Dec 31, 2022 | -448.00 Mn |
| Dec 31, 2022 | -448.00 Mn |
| Sep 30, 2022 | 1.29 Bn |
| Sep 30, 2022 | 1.29 Bn |
| Jun 30, 2022 | 130.00 Mn |
| Jun 30, 2022 | 130.00 Mn |
| Mar 31, 2022 | -1.59 Bn |
| Mar 31, 2022 | -1.59 Bn |
| Dec 31, 2021 | -1.15 Bn |
| Dec 31, 2021 | -1.15 Bn |
| Sep 30, 2021 | -615.00 Mn |
| Sep 30, 2021 | -615.00 Mn |
| Jun 30, 2021 | -242.00 Mn |
| Jun 30, 2021 | -242.00 Mn |
| Mar 31, 2021 | -342.00 Mn |
| Mar 31, 2021 | -342.00 Mn |
| Dec 31, 2020 | -627.00 Mn |
| Dec 31, 2020 | -627.00 Mn |
| Sep 30, 2020 | -1.15 Bn |
| Sep 30, 2020 | -1.15 Bn |
| Jun 30, 2020 | -35.65 Bn |
| Jun 30, 2020 | -35.65 Bn |
| Mar 31, 2020 | -129.00 Mn |
| Mar 31, 2020 | -129.00 Mn |
| Dec 31, 2019 | -615.00 Mn |
| Dec 31, 2019 | -615.00 Mn |
| Sep 30, 2019 | 1.38 Bn |
| Sep 30, 2019 | 1.38 Bn |
| Jun 30, 2019 | -140.00 Mn |
| Jun 30, 2019 | -140.00 Mn |
| Mar 31, 2019 | -27.00 Mn |
| Mar 31, 2019 | -27.00 Mn |
| Dec 31, 2018 | -283.00 Mn |
| Dec 31, 2018 | -283.00 Mn |
| Sep 30, 2018 | -963.00 Mn |
| Sep 30, 2018 | -963.00 Mn |
| Jun 30, 2018 | 687.00 Mn |
| Jun 30, 2018 | 687.00 Mn |
| Mar 31, 2018 | -447.00 Mn |
| Mar 31, 2018 | -447.00 Mn |
| Dec 31, 2017 | 201.00 Mn |
| Dec 31, 2017 | 201.00 Mn |
| Sep 30, 2017 | -109.00 Mn |
| Sep 30, 2017 | -109.00 Mn |
| Jun 30, 2017 | 318.00 Mn |
| Jun 30, 2017 | 318.00 Mn |
| Mar 31, 2017 | -684.00 Mn |
| Mar 31, 2017 | -684.00 Mn |
| Dec 31, 2016 | -119.00 Mn |
| Dec 31, 2016 | -119.00 Mn |
| Sep 30, 2016 | -199.00 Mn |
| Sep 30, 2016 | -199.00 Mn |
| Jun 30, 2016 | -4.30 Bn |
| Jun 30, 2016 | -4.30 Bn |
| Mar 31, 2016 | -1.46 Bn |
| Mar 31, 2016 | -1.46 Bn |
| Dec 31, 2015 | -297.00 Mn |
| Dec 31, 2015 | -297.00 Mn |
| Sep 30, 2015 | 745.00 Mn |
| Sep 30, 2015 | 745.00 Mn |
| Jun 30, 2015 | -12.51 Bn |
| Jun 30, 2015 | -12.51 Bn |
| Mar 31, 2015 | -873.00 Mn |
| Mar 31, 2015 | -873.00 Mn |
| Dec 31, 2014 | 2.51 Bn |
| Dec 31, 2014 | 2.51 Bn |
| Sep 30, 2014 | -2.28 Bn |
| Sep 30, 2014 | -2.28 Bn |
| Jun 30, 2014 | -359.00 Mn |
| Jun 30, 2014 | -359.00 Mn |
| Mar 31, 2014 | -797.00 Mn |
| Mar 31, 2014 | -797.00 Mn |
| Dec 31, 2013 | 123.00 Mn |
| Dec 31, 2013 | 123.00 Mn |
| Sep 30, 2013 | -964.00 Mn |
| Sep 30, 2013 | -964.00 Mn |
| Jun 30, 2013 | 233.00 Mn |
| Jun 30, 2013 | 233.00 Mn |
| Mar 31, 2013 | 1.49 Bn |
| Mar 31, 2013 | 1.49 Bn |
| Dec 31, 2012 | -206.00 Mn |
| Dec 31, 2012 | -206.00 Mn |
| Sep 30, 2012 | -1.81 Bn |
| Sep 30, 2012 | -1.81 Bn |
| Jun 30, 2012 | -202.00 Mn |
| Jun 30, 2012 | -202.00 Mn |
| Mar 31, 2012 | -204.00 Mn |
| Mar 31, 2012 | -204.00 Mn |